Evista (raloxifene) might help prevent breast cancer in postmenopausal women

March 1999

New research suggests that Evista (raloxifene) might help prevent breast cancer in postmenopausal women.

Women taking Evista for osteoporosis seem to have a 60% lower risk of developing breast cancer.

This is similar to the benefit that's seen with tamoxifen.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote